Patents by Inventor Michael Karin

Michael Karin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CXCR5 antibodies and compositions and uses thereof
    Patent number: 11958901
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to CXCR5. The antibodies can be afucosylated and exhibit increased ADCC compared with the otherwise identical fucosylated antibodies. The invention includes uses, and associated methods of using the antibodies.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: April 16, 2024
    Assignees: Pfizer Inc., The Regents of the University of California
    Inventors: Rachel Groth, William Brian Snyder, Xianjun Cao, Robert Joseph Dunn, Joseph Dal Porto, Michael Karin
  • TARGETING STROMA-CANCER INTERACTIONS IN CANCER
    Publication number: 20230341404
    Abstract: Provided herein are prognostic methods for determining median survival of subjects from a cancer such as a desmoplastic cancer, a fibrolytic cancer or a pancreatic ductal adenocarcinoma (PDAC) as well as methods for treating same.
    Type: Application
    Filed: April 24, 2023
    Publication date: October 26, 2023
    Inventors: Michael Karin, Hua Su
  • Methods for treating NLRP3 inflammasome-associated diseases, and methods of identifying agents useful therefor
    Patent number: 11617761
    Abstract: Provided herein are methods of treating NLRP3 inflammasome-associated diseases and disorders. Also, disclosed are methods for screening for agents useful in such methods.
    Type: Grant
    Filed: November 12, 2020
    Date of Patent: April 4, 2023
    Assignee: The Regents of the University of California
    Inventors: Michael Karin, Zhenyu Zhong
  • COMBINATION THERAPY FOR CANCER
    Publication number: 20230068698
    Abstract: Provided herein are methods and compositions for treating cancer through a combination of an inhibitor of macropinocytosis upregulation and an autophagy inhibitor. Also provided are methods and compositions for inducing cell death of cancer cells, and transgenic animal models regarding same.
    Type: Application
    Filed: January 13, 2021
    Publication date: March 2, 2023
    Inventors: Michael Karin, Hua Su
  • METHODS FOR TREATING MACROPHAGE-MEDIATED DISEASES, AND METHODS OF IDENTIFYING AGENTS USEFUL THEREFORE
    Publication number: 20220133770
    Abstract: Provided herein are methods of treating macrophage-mediated inflammatory diseases and disorders. Also, disclosed are methods for screening for agents useful in such methods.
    Type: Application
    Filed: February 4, 2020
    Publication date: May 5, 2022
    Inventors: Michael Karin, Elsa Sanchez-Lopez
  • METHODS FOR ENHANCING CANCER IMMUNOTHERAPY
    Publication number: 20210386828
    Abstract: Provided herein are methods of inducing expression of major histocompatibility complex (MHC) molecules on a cancer cell surface by inducing expression of one or more genes associated with MHC. Also disclosed are methods of screening for agents useful in treating cancer and methods of treating such cancers.
    Type: Application
    Filed: December 19, 2019
    Publication date: December 16, 2021
    Inventors: Shabnam Shalapour, Michael Karin
  • Hepatocytes with high regenerative capacity for liver repair
    Patent number: 11065280
    Abstract: The invention provides purified mammalian hybrid hepatocyte (HybHP) cells, compositions comprising HybHP cells, methods for purifying HybHP cells, methods for in vitro culture of HybHP cells, and methods for using HybHP cells to repopulate and/or treat the liver of a subject in need thereof.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: July 20, 2021
    Assignee: The Regents of the University of California
    Inventors: Joan Font-Burgada, Michael Karin
  • METHODS FOR TREATING NLRP3 INFLAMMASOME-ASSOCIATED DISEASES, AND METHODS OF IDENTIFYING AGENTS USEFUL THEREFOR
    Publication number: 20210154222
    Abstract: Provided herein are methods of treating NLRP3 inflammasome-associated diseases and disorders. Also, disclosed are methods for screening for agents useful in such methods.
    Type: Application
    Filed: November 12, 2020
    Publication date: May 27, 2021
    Inventors: Michael Karin, Zhenyu Zhong
  • ANTI-CXCR5 ANTIBODIES AND COMPOSITIONS AND USES THEREOF
    Publication number: 20210101970
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to CXCR5. The antibodies can be afucosylated and exhibit increased ADCC compared with the otherwise identical fucosylated antibodies. The invention includes uses, and associated methods of using the antibodies.
    Type: Application
    Filed: November 20, 2020
    Publication date: April 8, 2021
    Inventors: Rachel Groth, William Brian Snyder, Xianjun Cao, Robert Joseph Dunn, Joseph Dal Porto, Michael Karin
  • Anti-CXCR5 antibodies and compositions and uses thereof
    Patent number: 10875915
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to CXCR5. The antibodies can be afucosylated and exhibit increased ADCC compared with the otherwise identical fucosylated antibodies. The invention includes uses, and associated methods of using the antibodies.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: December 29, 2020
    Assignees: PFIZER INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Rachel Groth, William Brian Snyder, Xianjun Cao, Robert Joseph Dunn, Joseph Dal Porto, Michael Karin
  • Methods for treating NLRP3 inflammasome-associated diseases, and methods of identifying agents useful therefor
    Patent number: 10869880
    Abstract: Provided herein are methods of treating NLRP3 inflammasome-associated diseases and disorders. Also, disclosed are methods for screening for agents useful in such methods.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: December 22, 2020
    Assignee: The Regents of the University of California
    Inventors: Michael Karin, Zhenyu Zhong
  • Chemoimmunotherapy for epithelial cancer
    Patent number: 10722523
    Abstract: The invention provides a method for treating cancer in a subject in need thereof, wherein said subject comprises cancer tissue that ‘contains epithelial cancer cells and immunosuppressive 8 cells, and wherein said method comprises administering to said subject a therapeutically effective amount of a) one or more first composition that pauses—immunogenic eel’ death and/or of said epithelial cancer cells, and b) one or more second composition that reduces one or both of the number and function of said immunosuppressive B cells in said cancer.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: July 28, 2020
    Assignee: The Regents of the University of California
    Inventors: Michael Karin, Shabnam Shalapour
  • METHODS FOR TREATING NLRP3 INFLAMMASOME-ASSOCIATED DISEASES, AND METHODS OF IDENTIFYING AGENTS USEFUL THEREFOR
    Publication number: 20190388454
    Abstract: Provided herein are methods of treating NLRP3 inflammasome-associated diseases and disorders. Also, disclosed are methods for screening for agents useful in such methods.
    Type: Application
    Filed: June 25, 2019
    Publication date: December 26, 2019
    Inventors: Michael Karin, Zhenyu Zhong
  • METHODS FOR INHIBITING NONALCOHOLIC STEATOHEPATITIS, NONALCOHOLIC FATTY LIVER DISEASE, AND/OR DE NOVO LIPOGENESIS
    Publication number: 20190351003
    Abstract: Provided herein are methods of treating nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), and/or elevated de novo lipogenesis (DNL) by inhibiting caspase-2 activity or expression. Also disclosed are methods of screening for agents useful in such methods.
    Type: Application
    Filed: February 7, 2018
    Publication date: November 21, 2019
    Inventors: Michael Karin, Juyoun Kim
  • ANTI-CXCR5 ANTIBODIES AND COMPOSITIONS AND USES THEREOF
    Publication number: 20190169283
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to CXCR5. The antibodies can be afucosylated and exhibit increased ADCC compared with the otherwise identical fucosylated antibodies. The invention includes uses, and associated methods of using the antibodies.
    Type: Application
    Filed: November 28, 2018
    Publication date: June 6, 2019
    Inventors: Rachel Groth, William Brian Snyder, Xianjun Cao, Robert Joseph Dunn, Joseph Dal Porto, Michael Karin
  • HEPATOCYTES WITH HIGH REGENERATIVE CAPACITY FOR LIVER REPAIR
    Publication number: 20180369291
    Abstract: The invention provides purified mammalian hybrid hepatocyte (HybHP) cells, compositions comprising HybHP cells, methods for purifying HybHP cells, methods for in vitro culture of HybHP cells, and methods for using HybHP cells to repopulate and/or treat the liver of a subject in need thereof.
    Type: Application
    Filed: May 3, 2016
    Publication date: December 27, 2018
    Inventors: Joan Font-Burgada, Michael Karin
  • NOVEL CHEMOIMMUNOTHERAPY FOR EPITHELIAL CANCER
    Publication number: 20180264004
    Abstract: The invention provides a method for treating cancer in a subject in need thereof, wherein said subject comprises cancer tissue that ‘contains epithelial cancer cells and immunosuppressive 8 cells, and wherein said method comprises administering to said subject a therapeutically effective amount of a) one or more first composition that pauses—immunogenic eel’ death and/or of said epithelial cancer cells, and b) one or more second composition that reduces one or both of the number and function of said immunosuppressive B cells in said cancer.
    Type: Application
    Filed: March 17, 2016
    Publication date: September 20, 2018
    Applicant: The Regents of the University of California
    Inventors: Michael Karin, Shabnam Shalapour
  • Animal model of nash-induced hepatocellular carcinoma and methods for developing specific therapeutics
    Patent number: 10034462
    Abstract: The invention provides a non-human animal model for non-alcoholic steatohepatitis (NASH)-induced heptocellular carcinoma, methods of screening for agents for treating heptocellular carcinoma, methods of screening for targets useful in suppressing NASH progression to heptocellular carcinoma, methods of treating heptocellular carcinoma, and compositions for treating the same.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: July 31, 2018
    Assignee: The Regents of the University of California
    Inventors: Michael Karin, Atsushi Umemura, Hayato Nakagawa
  • Fibrotic non-human animal, and use thereof
    Patent number: 9565840
    Abstract: The present invention provides a non-human animal IKK? which shows fibrosis of tissue, since it lacks IKK? gene in a myofibroblast- and/or smooth muscle cell-specific manner. Since the non-human animal shows pathology highly similar to scleroderma, it is extremely useful as an animal model of scleroderma.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: February 14, 2017
    Assignees: KYOTO UNIVERSITY, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Noboru Ashida, Masayuki Yokode, Michael Karin, Dat Nguyen Tien
  • ANIMAL MODEL OF NASH-INDUCED HEPATOCELLULAR CARCINOMA AND METHODS FOR DEVELOPING SPECIFIC THERAPEUTICS
    Publication number: 20160360735
    Abstract: The invention provides a non-human animal model for non-alcoholic steatohepatitis (NASH)-induced heptocellular carcinoma, methods of screening for agents for treating heptocellular carcinoma, methods of screening for targets useful in suppressing NASH progression to heptocellular carcinoma, methods of treating heptocellular carcinoma, and compositions for treating the same.
    Type: Application
    Filed: June 10, 2016
    Publication date: December 15, 2016
    Inventors: Michael Karin, Atsushi Umemura, Hayato Nakagawa